- Home
- CB vs HUMAW Comparison
CB vs HUMAW Comparison
Compare CB & HUMAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- HUMAW
- Stock Information
- Founded
- CB 1985
- HUMAW 2004
- Country
- CB Switzerland
- HUMAW United States
- Employees
- CB N/A
- HUMAW 220
- Industry
- CB Property-Casualty Insurers
- HUMAW Biotechnology: Pharmaceutical Preparations
- Sector
- CB Finance
- HUMAW Health Care
- Exchange
- CB Nasdaq
- HUMAW Nasdaq
- Market Cap
- CB 117.0B
- HUMAW N/A
- IPO Year
- CB 1993
- HUMAW N/A
- Fundamental
- Price
- CB $285.24
- HUMAW $0.41
- Analyst Decision
- CB Buy
- HUMAW
- Analyst Count
- CB 15
- HUMAW 0
- Target Price
- CB $308.00
- HUMAW N/A
- AVG Volume (30 Days)
- CB 1.5M
- HUMAW 14.2K
- Earning Date
- CB 07-22-2025
- HUMAW 03-21-2025
- Dividend Yield
- CB 1.34%
- HUMAW N/A
- EPS Growth
- CB N/A
- HUMAW N/A
- EPS
- CB 20.78
- HUMAW N/A
- Revenue
- CB $56,307,000,000.00
- HUMAW N/A
- Revenue This Year
- CB N/A
- HUMAW N/A
- Revenue Next Year
- CB $6.03
- HUMAW N/A
- P/E Ratio
- CB $13.95
- HUMAW N/A
- Revenue Growth
- CB 8.74
- HUMAW N/A
- 52 Week Low
- CB $251.42
- HUMAW $1.18
- 52 Week High
- CB $306.91
- HUMAW $1.34
- Technical
- Relative Strength Index (RSI)
- CB 43.98
- HUMAW N/A
- Support Level
- CB $282.22
- HUMAW N/A
- Resistance Level
- CB $288.94
- HUMAW N/A
- Average True Range (ATR)
- CB 4.01
- HUMAW 0.00
- MACD
- CB -0.60
- HUMAW 0.00
- Stochastic Oscillator
- CB 16.63
- HUMAW 0.00
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About HUMAW Humacyte Inc. Warrant
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.